Mathilde/NLI4PR huggingface dataset:
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Eligibility criteria:
-  Male, at least 12 years old, with severe hemophilia A undergoing major elective major
             surgery requiring FVIII replacement for at least 6 days. Negative FVIII inhibitor test
             at screening and no past history of inhibitor.

          -  Previously treated with at least 150 exposure days to any Factor VIII product

          -  Normal hepatic and renal function tests and no other bleeding disorder
Male
No healthy subjects accepted to join the trial.
Subject must be at least 12 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 33-year-old woman comes to clinic complaining of progressive fatigue, decreased appetite, and 11-lb weight loss in the past 2 months.  She uses levothyroxine because of the previously diagnosed Hashimoto disease. She has no other medical conditions and does not use tobacco, alcohol, or illicit drugs.  Physical examination shows a generalized increase in pigmentation of the skin.  Measurement of serum cortisol before and after administration of exogenous adrenocorticotropic hormone (ACTH) shows no difference in the levels. Stable glucocorticoid replacement therapy starts for her with the diagnosis for primary adrenal insufficiency (Addison disease)

Patient's own account: I went to the clinic because I was really suffering from fatigue and decreased appetite and I also lost 11 pounds over the past two months. I'm just 33 years old so that's not normal, especially for a woman. I take levothyroxine because I have been diagnosed with Hashimoto disease. I don't have any other medical condition, and I don't smoke I don't drink, and I don't do drugs. They also did my physical examination and they saw that I had an increase in pigmentation of my skin. They measured my cortisol level before and after giving me some ACTH hormone, and the results came back with no difference whatsoever. The doctor told me I have Addison disease and put me under glucocorticoid therapy.

Clinical trial: Glucocorticoid Treatment in Addison's Disease

Eligibility criteria:
Inclusion Criteria:

          -  Patients with verified Addison's disease on stable treatment.

        Exclusion Criteria:

          -  Insulin treated Diabetes Mellitus, cardiovascular disease,malignant disease,
             pregnancy.

          -  Treatment with glucocorticoids or drugs that interfere with cortisol metabolism
             (antiepileptics, rifampicin, St. John's wart).
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 70 Years

Eligibility (NLI label): Entailment
Patient case (clinical description): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient's own account: I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Clinical trial: The Efficacy and Safety of Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchymal Stem Cells in Infertile Women With Thin Endometrium or Endometrial Scarring

Eligibility criteria:
Inclusion Criteria:

          1. Infertile patients with clear fertility desires

          2. Diagnosed with thin endometrium or endometrial scarring for whom drugs and surgical
             interventions were ineffective

          3. 20-42 years old

          4. Normal ovarian function or with frozen embryos

          5. Willing to actively cooperate with postoperative follow-up

        Exclusion Criteria:

          1. With abnormal chromosome karyotype

          2. With other uterine diseases including large intramural myomas, severe endometriosis,
             severe adenomyosis, severe congenital uterine malformations, endometrial tuberculosis,
             vaginitis and endometritis

          3. Systemic diseases: hypertension, diabetes, and so on

          4. Contraindications to pregnancy

          5. Contraindications to hormone replacement therapy

          6. Medical history of pelvic tumors or receiving pelvic radiotherapy

          7. Involved in other clinical studies

          8. Unable to adhere to the follow-up
Female
No healthy subjects accepted to join the trial.
Subject must be at least 20 Years old.
Subject must be at most 42 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): An 8-year-old boy is brought to the clinic by his parents because of weakness and difficulty of standing up from a sitting position. The mother is healthy but had a brother who died in his 20th after being disabled and using wheelchairs in the last few years of his life. Physical examination shows 3/5 lower extremity muscle strength and enlarged calf muscles. The other physical examination and vital signs are unremarkable. Muscle biopsy showed absence of dystrophin protein. The patient is diagnosed with DMD.

Patient's own account: I brought my  8-year-old son to the doctor's clinic. He was struggling to stand up from a chair for the past few days. My wife is healthy but she was pretty worried since his brother died in his 20s after being disabled and using a wheelchair for the last years of his life. The doctor did an exam which highlighted weakness in the leg muscles and unusually large calf muscles. The rest of the exam was fine, and his vitals were normal. My son did a muscle biopsy, and it showed that the protein important for muscle strength and function is missing. The doctor diagnosed him with Duchenne muscular dystrophy.

Clinical trial: Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

Eligibility criteria:
Inclusion Criteria:

          -  Male

          -  Age 7 years to 100 years

          -  Ability to ambulate for 10 meters. Assistive devices are allowed.

          -  Diagnosis of DMD confirmed by at least one the following:

          -  On stable dose of prednisone, prednisolone or deflazacort for at least 12 months prior
             to screening.

          -  Participants who are on stable dose of any combination of the following compounds
             (creatine, glutamine, coenzyme Q10, vitamin E, C or D, JUVEN, arginine, calcium) must
             have taken these medications for at least 2 months prior to screening. Subjects are
             not required to take these medications to participate in the study.

          -  All other herbs, supplements or green tea (other than those noted above) have been
             discontinued 3 months prior to screening.

          -  Ability to provide reproducible QMT bicep score with no more than 15% variation
             between scores during screening.

          -  Normal blood clotting ability evidenced by a platelet function assessment (PFA).

        Exclusion Criteria:

          -  Currently enrolled in another treatment clinical trial.

          -  History of significant concomitant illness or significant impairment of renal or
             hepatic function.

          -  History of impairment of blood clotting ability (as evidenced by increased PT/PTT or
             PFA over the upper limit of normal (ULN)).

          -  Recent cerebral or retinal hemorrhage.

          -  History of bleeding diathesis or gastric ulcer.
Male
No healthy subjects accepted to join the trial.
Subject must be at least 7 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 9-year-old girl is brought to the office for evaluation of short stature and overweight body habitus. The patient's mother and father are 170 cm and 181 cm tall, respectively.  On physical examination, the patient's height is in the 5th percentile of her age.  Other findings include low-set ears, a high arched palate, a webbed neck, and cubitus valgus.  Chromosomal analysis reveals a 45, XO karyotype.

Patient's own account: I took my 9-year-old daughter to the doctor because my mother-in-law kept saying she seemed small and overweight. My husband and I are 170 cm and 181 cm tall, respectively. The physical health highlighted that she is in the 5th percentile of her age. The doctor said that she has low-set ears, a high-arched palate, a webbed neck, and cubitus valgus. She also did a chromosomal analysis, which revealed a 45, XO karyotype.

Clinical trial: Parent-Based Treatment for Pediatric Overweight

Eligibility criteria:
Inclusion Criteria:

          -  Ages 13-17

          -  Male and female

          -  Living with at least one parent or guardian who is willing to participate in treatment

          -  A BMI percentile >85% for gender and age (e.g., overweight or at risk for overweight)

        Exclusion Criteria:

          -  Current psychotic illness

          -  Current alcohol/drug dependence

          -  Active suicidality

          -  Eating disorders (e.g., binge eating disorder)

          -  History of bariatric surgery

          -  Medication associated with significant weight changes (e.g., antipsychotics)

          -  Serious medical or physical conditions resulting in significant weight changes (e.g.,
             pregnancy, genetic disorders).

          -  Complications of obesity that contraindicate moderate physical activity (e.g.
             orthopedic disorders)
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 13 Years old.
Subject must be at most 17 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 67-year-old woman comes to the clinic due to recent episode of choking, dysphagia, and cough.  Her other medical problems include hypertension, dyslipidemia, and osteoarthritis.  She does not smoke or use alcohol. She lives with her husband and she is able to do her own daily activities. She used to teach elementary school. Blood pressure is 135/80 mm Hg.  The patient's breath smells bad. Other physical examinations are normal.  A barium swallow study reveals an abnormality in the upper esophagus with an outpouching at the junction of the lower part of the throat and the upper portion of the esophagus.

Patient's own account: I'm a 67-year-old lady, and I went to the clinic due to nonstop choking, difficulty swallowing, and coughing. I also suffer from hypertension, cholesterol, and osteoarthritis. I do not smoke or drink alcohol. I live with my husband, and we are independent retired elementary school teachers. During the exam, my blood pressure was 135/80 mm Hg. The doctor told me I had a smelly breath. How embarrassing! The rest of my physical exam was normal. I did a barium swallow test, which is an X-ray of my throat, which revealed a problem in the upper part of my esophagus, where there's a small pouch or bulge at the spot where my throat meets the esophagus.

Clinical trial: Study of the Response of Human Small Blood Vessels

Eligibility criteria:
Patients (men and nonpregnant women) with systemic hypertension, patients with
        hypercholesterolemia, and normal volunteers.

        All blood pressure recordings must be consistently elevated.

        No renovascular hypertension or other etiologies for elevated blood pressure.

        No definite evidence of accelerated or malignant hypertension (diastolic pressures above
        115 mmHg, with associated encephalopathic changes, papilledema, progressive renal failure,
        or congestive heart failure), or serious intercurrent illness.

        Patients in whom withdrawal of antihypertensive medications is considered hazardous are
        ineligible.

        Patients in whom the blood pressure remains at normal levels 2 weeks after withdrawal of
        antihypertensive treatment will be closely monitored until they become hypertensive, at
        which time they will undergo the study. Patients in whom blood pressure does not increase
        after 2 months of discontinuation of therapy will be excluded from the study.

        Patients with coexistent hypertension and hypercholesterolemia are ineligible.

        Normal volunteers who are not taking any kind of medication are eligible.

        No history of diabetes, peripheral vascular disease, coagulopathy, or any other disease
        predisposing to vasculitis or Raynaud's phenomenon.

        No history of keloid formation.

        All patients must be capable of giving informed consent for all procedures.
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers



Eligibility (NLI label): Contradiction
Patient case (clinical description): A 31-year-old woman comes to the office due to 3 days of rash on her left arm.  The lesion is mildly pruritic but not painful.  She is otherwise healthy and occasionally takes ibuprofen during the first few days of her menstrual period.  Temperature is 37 C, blood pressure is 110/75 mm Hg, and pulse is 95/min. The lesion is like a target sign known as erythema migrans. She recently went for an adventure trip in New Hampshire. The patient is diagnosed with Lyme disease.

Patient's own account: I went to the clinic because I had a rash on my left arm for three days, and the lesion started to be putrid, but it was not painful. I'm a 31-year-old healthy woman and the only medication I use is ibuprofen when I get my periods. They took my temperature, which turned out to be 37°C and took my blood pressure which was 110/75 and my pulse 95. My lesion is round like a target sign. I just came back from a New Hampshire road trip with my friends. Unfortunately, the doctor diagnosed me with Lyme disease.

Clinical trial: Patient's Pretreatment Expectations About Post-Lyme Symptoms

Eligibility criteria:
Inclusion Criteria:

          -  erythema migrans

        Exclusion Criteria:

          -  pregnancy or lactation

          -  immunocompromised

          -  taking antibiotic with antiborrelial activity within 10 days
No condition on gender to be admitted to the trial.
Accepts Healthy Volunteers
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment
Patient case (clinical description): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient's own account: I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Clinical trial: Effect of Intrauterine Navigation Using Intrauterine Insemination Catheter for Mock Embryo Transfer Prior to Day 3 Embryo Transfer on Pregnancy Rate: A Pilot Study

Eligibility criteria:
Inclusion Criteria:

        We included nulliparous patients who were < 42 years of age with body mass index (BMI) < 30
        kg/m2 and normal endometrial cavity, used fresh sperm or oocytes, had two or more embryos
        available for transfer on day 3 post ovum pick-up (OPU), and no more than 3 previous
        unsuccessful ART cycles

        Exclusion Criteria:

        Patients with uterine fibroids, uterine anomalies, intra-uterine adhesions, and uterine
        polyps, patients with chronic diseases in the as uncontrolled diabetes or hypertension, or
        if the patient had difficult mock ET . patients with severe male factors for infertility
        requiring surgical retrieval of sperms were excluded from the study.

        -
Female
Accepts Healthy Volunteers
Subject must be at least 18 Years old.
Subject must be at most 42 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 23-year-old female has prolonged oral bleeding immediately after a tooth extraction.  Despite several interventions, the bleeding persists for hours and stops only after desmopressin (DDAVP) administration.  The patient has heavy menstrual cycles each month.  She has no other medical problems and takes no medications.  Her mother and grandmother have also had excessive bleeding during menstrual period.  Review of systems is positive for mild bruising on his legs. Laboratory findings reveal a normal platelet count and an abnormal ristocetin cofactor assay, as well as CB <= 0.30 IU/mL and FVIII:C <= 0.40 IU/mL.

Patient's own account: I'm a 23 woman and I went to the ER because of non-stop bleeding after my tooth extraction. I tried to make the bleeding stop but it just kept going for hours and it finally stopped when I took some medication called DDAVP. I usually have heavy periods, just like my mom and grandma had. I don't have any other medical condition and I don't take any other medication. The doctor noticed the bruises on my legs. I had to do some lab tests. I had a normal platelet count but an abnormal ristocetin cofactor assay. I had low CB and FVIII:C levels.

Clinical trial: Registry of Patients With Von WilLEbrand Disease Treated With Voncento®

Eligibility criteria:
Inclusion Criteria:

          -  Patients suffering from constitutional von Willebrand disease for whom Desmopressin
             treatment is deemed ineffective or contraindicated

          -  Patients suffering from von Willebrand disease and being treated or having been
             treated with Voncento® for the treatment of surgical and non-surgical bleeding
             episodes, the prophylaxis of surgical and non-surgical bleedings

          -  Patients with no history or suspicion of inhibitors (judged on previous efficacy)

        Exclusion Criteria:

          -  Refusal of the patient or the patient's legal representative to take part in the
             study;

          -  Existence of a contraindication to the use of Voncento® treatment
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Contradiction
Patient case (clinical description): A 20-year-old man comes to the emergency due to bleeding after a tooth extraction.  The bleeding has persisted for approximately 30 minutes despite constant direct pressure.  He is a known case of Hemophilia type A treated with FVIII. Blood pressure is 95/60 mm Hg and pulse is 105/min. His weight is 70 Kg. Family history is positive for Hemophilia type A in his maternal uncle. He also has a lipoma on his left arm which he plans to remove surgically. His FVIII activity is 40%.

Patient's own account: I got my tooth extracted and I could not stop bleeding for 30 min. I'm a 20 yo dude but I have Hemophilia type A treated with FVIII. My blood pressure was 95/60 and my pulse 105/min. I'm 70 kg. My uncle on my mom's side also has type A hemophilia. I also have a fatty swelling on my left arm and I was supposed to remove it. My FVIII activity was 40%.

Clinical trial: Therapeutic Exercise in Patients With Hemophilia

Eligibility criteria:
Inclusion Criteria:

          -  Clinical diagnosis of hemophilia type A or hemophilia type B.

          -  Knee, elbow or ankle arthropathy caused by hemophilia

          -  Pharmacological treatment based on using VIII or IX factor concentrates.

        Exclusion Criteria:

          -  Presence of VIII FIX inhibitors.

          -  Having received anti-inflammatory treatment using Arcoxia (Etoricoxib)

          -  Having undergone a surgical intervention at the target joint.

          -  Patients enrolled in other research which implies doing physical exercise.
Male
No healthy subjects accepted to join the trial.
Subject must be at least 30 Years old.
Subject must be at most 45 Years

Eligibility (NLI label): Contradiction
Patient case (clinical description): A 32-year-old woman comes to the hospital with vaginal spotting.  Her last menstrual period was 10 weeks ago. She has regular menses lasting for 6 days and repeating every 29 days. Medical history is significant for appendectomy and several complicated UTIs. She has multiple male partners, and she is inconsistent with using barrier contraceptives. Vital signs are normal.  Serum β-hCG level is 1800 mIU/mL, and a repeat level after 2 days shows an abnormal rise to 2100 mIU/mL.  Pelvic ultrasound reveals a thin endometrium with no gestational sac in the uterus.

Patient's own account: I just turned 32 and last morning I woke up with strange blood stains on my underwear. My last periods were more than 2 months ago, which is unusual for me because I used to have regular periods lasting for 6 days every 29 days, more or less. I had several UTIs in the past. I also had appendicitis. I'm currently seeing several men and, to be honest, some of them do struggle to wear a condom. I went to the hospital to check myself up and they told me that my vitals were normal. I also had a blood test on Monday, and my β-hCG level was 1800 mIU/mL, and then on Wednesday, it went up to 2100 mIU/mL. The gynecologist also did an ultrasound and she told me that, hopefully, there was no ovule.

Clinical trial: Serum Kisspeptin: a Predictive Marker of Miscarriage or Not?

Eligibility criteria:
Inclusion Criteria:

          -  Women who have a positive pregnancy test following IVF or frozen-thawed transfer

        Exclusion Criteria:

          -  Women with renal failure are excluded due to assay interference with kisspeptin
             measurement
Female
No healthy subjects accepted to join the trial.



Eligibility (NLI label): Contradiction